BRAIN Biotech AG

XTRA:BNN Stock Report

Market Cap: €53.3m

BRAIN Biotech Future Growth

Future criteria checks 1/6

BRAIN Biotech is forecast to grow earnings and revenue by 56.9% and 10.1% per annum respectively while EPS is expected to grow by 57.2% per annum.

Key information

56.9%

Earnings growth rate

57.20%

EPS growth rate

Chemicals earnings growth33.3%
Revenue growth rate10.1%
Future return on equityn/a
Analyst coverage

Low

Last updated25 Feb 2026

Recent future growth updates

Analysts Have Been Trimming Their BRAIN Biotech AG (ETR:BNN) Price Target After Its Latest Report

Jan 18
Analysts Have Been Trimming Their BRAIN Biotech AG (ETR:BNN) Price Target After Its Latest Report

Recent updates

Production Disruptions And Weak Margins Will Eventually Benefit Consolidated Enzyme Platform

Catalysts About BRAIN Biotech BRAIN Biotech AG is a European industrial biotechnology company that develops and produces enzyme based and bio based solutions for food, beverages and other industrial applications. What are the underlying business or industry changes driving this perspective?

Biological Solutions And Gene Editing Will Reshape Industrial Processes Over The Next Decade

Catalysts About BRAIN Biotech BRAIN Biotech develops and produces enzyme and microbial solutions for industrial and pharmaceutical applications. What are the underlying business or industry changes driving this perspective?

Analysts Have Been Trimming Their BRAIN Biotech AG (ETR:BNN) Price Target After Its Latest Report

Jan 18
Analysts Have Been Trimming Their BRAIN Biotech AG (ETR:BNN) Price Target After Its Latest Report

Market Cool On BRAIN Biotech AG's (ETR:BNN) Revenues Pushing Shares 28% Lower

Dec 22
Market Cool On BRAIN Biotech AG's (ETR:BNN) Revenues Pushing Shares 28% Lower

It's A Story Of Risk Vs Reward With BRAIN Biotech AG (ETR:BNN)

Nov 07
It's A Story Of Risk Vs Reward With BRAIN Biotech AG (ETR:BNN)

Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?

Aug 26
Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?

A Piece Of The Puzzle Missing From BRAIN Biotech AG's (ETR:BNN) 38% Share Price Climb

Jul 23
A Piece Of The Puzzle Missing From BRAIN Biotech AG's (ETR:BNN) 38% Share Price Climb

Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 27% Bounce

Nov 12
Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 27% Bounce

Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 50% Bounce

Sep 24
Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 50% Bounce

BRAIN Biotech AG (ETR:BNN) Screens Well But There Might Be A Catch

Aug 06
BRAIN Biotech AG (ETR:BNN) Screens Well But There Might Be A Catch

Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?

Jun 29
Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?

BRAIN Biotech AG (ETR:BNN) Shares Could Be 36% Below Their Intrinsic Value Estimate

Apr 19
BRAIN Biotech AG (ETR:BNN) Shares Could Be 36% Below Their Intrinsic Value Estimate

BRAIN Biotech AG's (ETR:BNN) P/S Still Appears To Be Reasonable

Mar 28
BRAIN Biotech AG's (ETR:BNN) P/S Still Appears To Be Reasonable

Is BRAIN Biotech (ETR:BNN) A Risky Investment?

Feb 16
Is BRAIN Biotech (ETR:BNN) A Risky Investment?

Here's Why BRAIN Biotech (ETR:BNN) Can Afford Some Debt

Sep 13
Here's Why BRAIN Biotech (ETR:BNN) Can Afford Some Debt

Earnings and Revenue Growth Forecasts

XTRA:BNN - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/202864-5N/AN/A2
9/30/202767-2-7-45
9/30/202657-7-8-55
12/31/202549-11-10-8N/A
9/30/202550-12-11-9N/A
6/30/202554-12-9-8N/A
3/31/202554-14-7-5N/A
12/31/202456-13-6-4N/A
9/30/202456-11-5-4N/A
6/30/202456-9-5-2N/A
3/31/202456-8-4-2N/A
12/31/202355-8-7-5N/A
9/30/202356-8-7-4N/A
6/30/202355-7-11-5N/A
3/31/202354-7-11-6N/A
12/31/202254-7-9-3N/A
9/30/202250-7-8-1N/A
6/30/202248-8-3-2N/A
3/31/202244-8-4-1N/A
12/31/202141-4-3-2N/A
9/30/202139-5-5-4N/A
6/30/202137-6-5-2N/A
3/31/202137-6-6-5N/A
12/31/202037-11-9-6N/A
9/30/202039-10-8-5N/A
6/30/202041-9-11-4N/A
3/31/202041-12-11-5N/A
12/31/201941-12-10-4N/A
9/30/201940-11N/A-3N/A
6/30/201939-9N/A-4N/A
3/31/201937-7N/A-5N/A
12/31/201833-7N/A-7N/A
9/30/201829-8N/A-5N/A
6/30/201827-9N/A-8N/A
3/31/201825-8N/A-6N/A
12/31/201726-7N/A-4N/A
9/30/201726-10N/A-6N/A
6/30/201726-14N/A-6N/A
3/31/201726-14N/A-6N/A
12/31/201625-17N/A-6N/A
9/30/201625-15N/A-9N/A
6/30/201624-10N/A-8N/A
3/31/201624-9N/A-6N/A
12/31/201524-7N/A-5N/A
9/30/201524-6N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BNN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BNN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BNN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BNN's revenue (10.1% per year) is forecast to grow faster than the German market (5.8% per year).

High Growth Revenue: BNN's revenue (10.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BNN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/03 18:43
End of Day Share Price 2026/03/03 00:00
Earnings2025/12/31
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BRAIN Biotech AG is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas MeyerBaader Helvea Equity Research
Jan KochDeutsche Bank
Yi-Dan WangDeutsche Bank